BRIC Diabetes Care Devices Market Size Analysis:

BRIC Diabetes Care Devices Market was valued at USD 3.15 billion in 2023 and is expected to reach USD 7.55 billion by 2032, growing at a CAGR of 10.13% from 2024 to 2032.

The BRIC Diabetes Care Devices Market report is a comprehensive statistical analysis of diabetes incidence and prevalence in Brazil, Russia, India, and China, providing insights into disease burden by country. It features prescription trends by device type, showing the uptake of insulin pumps, CGMs, and blood glucose monitors by regions. The report also investigates device volume patterns using historical and predicted sales data to monitor market performance. It further offers healthcare spending trends by the type of payer, classifying spending under government, commercial, private, and out-of-pocket payment systems. These differentiated data-driven insights elucidate the developing environment of diabetes treatment in BRIC countries.

BRIC Diabetes Care Devices Market Dynamics

Drivers

• Rising Diabetes Prevalence and Increasing Awareness Initiatives are driving market growth.

The BRIC nations (Brazil, Russia, India, and China) are also experiencing a rapid increase in diabetes incidence due to sedentary lifestyles, poor diets, and genetic factors. China and India together had close to 40% of the world's diabetic population in 2023, as estimated by the International Diabetes Federation (IDF. Governments and health agencies are actively initiating awareness programs and screening initiatives to encourage early diagnosis and control. For instance, India's "National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS)" focuses on improving the accessibility of diabetes care. Further, innovations in blood glucose monitoring devices, such as continuous glucose monitoring (CGM) systems, are becoming increasingly popular due to their ease of use. The increasing focus on diabetes education and preventive monitoring is a major force driving the BRIC diabetes care devices market.

• Technological Advancements in Diabetes Care Devices are accelerating the market to grow.

The BRIC region is witnessing accelerating developments in diabetes care technology, resulting in the uptake of novel monitoring and insulin delivery solutions. Continuous glucose monitors (CGM) and smart insulin pens are becoming popular, providing real-time tracking of glucose levels and pain-free insulin injections. In August 2024, Medtronic obtained FDA clearance for its Simplera™ CGM, a fully disposable CGM system that removes overtape requirements, simplifying diabetes management. In the same vein, Insulet Corporation launched its Omnipod 5 Automated Insulin Delivery System for type 2 diabetes patients, furthering the trend toward automated and convenient diabetes management. With increasing investments in digital health and AI-based diabetes management platforms, patients in BRIC nations are enjoying more efficient and precise treatment options, driving market growth.

Restraint

• High Cost and Limited Accessibility of Advanced Diabetes Care Devices

One of the key controls in the BRIC Diabetes Care Devices Market is the excessive price of sophisticated diabetes care devices like continuous glucose monitors (CGMs) and insulin pumps, which makes them unavailable to much of the population. Whereas urban centers in BRIC nations have access to advanced healthcare infrastructure, rural areas tend to suffer from limited availability of these devices because of few healthcare facilities and financial constraints. For instance, in India and Brazil, the majority of diabetic patients continue to use conventional blood glucose meters instead of CGMs because of costs. Moreover, poor reimbursement strategies and the absence of comprehensive healthcare coverage in some areas further limit patient access to new diabetes care solutions. Consequently, the penetration of high-end diabetes devices is still uneven, holding back overall market growth.

Opportunities

• The BRIC Diabetes Care Devices Market presents a significant opportunity with the rising adoption of digital health technologies and telemedicine solutions.

As internet penetration and smartphone adoption grow in these nations, remote patient monitoring and digital diabetes management are gaining momentum. For example, India and China have seen a dramatic rise in mobile health applications that facilitate real-time glucose monitoring and teleconsultation with healthcare professionals. Governments and individual players are spending on digital health infrastructure, reducing the efficiency and accessibility of managing diabetes, particularly in rural and underserved segments. The implementation of artificial intelligence (AI) in diabetes devices is also changing the game with personalized treatment regimes, increased patient compliance, and better management of the disease as a whole. All this is a high-return opportunity for the market players to increase their size and develop cutting-edge technology-led diabetes care products.

Challenges

• One of the key issues in the BRIC Diabetes Care Devices Market is the absence of a uniform regulatory framework among these countries, posing hurdles for device makers.

Each country maintains unique medical device approval procedures, and manufacturers have to cross intricate and time-consuming regulatory hurdles. For instance, whereas registration for importing medical devices is very strict in China, India has been overhauling its regulation environment such that becoming compliant is a moving target for industry players. This regulatory inconsistency slows product launches and raises the cost of compliance. Furthermore, local manufacturing requirements and changing import bans complicate market entry even further. Firms need to spend significantly on regulatory know-how and have country-specific plans in place to maintain compliance, which can discourage new entrants and retard the uptake of innovative diabetes care products in these high-growth economies.

BRIC Diabetes Care Devices Market Segmentation Analysis

By Product 

The Insulin Delivery Devices segment dominated the BRIC diabetes care devices market with a 55.26 % market share in 2023 because of the growing number of patients suffering from insulin-dependent diabetes and the accelerating use of sophisticated insulin delivery technologies. As a high percentage of diabetes patients need insulin therapy, products such as syringes, pumps, and insulin pens have experienced extensive usage. The convenience and reliability of contemporary insulin delivery devices, including smart insulin pens and automatic insulin pumps, have boosted patient compliance and treatment results. Moreover, government initiatives in BRIC countries, especially China and India, have increased access to insulin therapy through price subsidies and reimbursement schemes. The appeal for minimally invasive and easy-to-use insulin delivery options, combined with the continued improvement in technology, has cemented the segment's leadership in 2023.

The Blood Glucose Monitoring Devices segment is expected to grow at the fastest rate in the forecast years, led by growing awareness of diabetes care, technology advancements, and the trend towards real-time glucose monitoring. Continuous glucose monitors (CGMs) and self-monitoring blood glucose (SMBG) meters are gaining popularity as they can offer real-time glucose values, lowering the risk of complications and enhancing diabetes control. The adoption of digital health technologies, including smartphone connectivity and cloud-based data tracking, is also driving demand further. Further, reducing device prices, government-sponsored diabetes screening initiatives, and the increasing preference for non-invasive monitoring solutions are likely to drive market growth. With BRIC nations continuing to focus on preventive care and early diagnosis of diabetes, blood glucose monitoring device adoption will increase in the forecast period.

By Distribution Channel

The Hospital Pharmacies segment dominated the BRIC diabetes care devices market with a 54.26% market share in 2023 because of the large number of hospital visits related to diabetes and the growth in the number of patients who are undergoing special treatment in medical facilities. The hospitals are main centers for treating, managing, and diagnosing diabetes, thereby creating a constant demand for blood glucose monitoring systems and insulin delivery devices. In addition, hospital pharmacies stock a broad selection of sophisticated diabetes care products, such as continuous glucose monitors (CGMs) and insulin pumps, that need to be set up and used under medical supervision. With robust procurement power, bulk discounts for large purchases, and insurance coverage for hospital-based diabetes care, hospital pharmacies have emerged as the distribution channel of choice for both healthcare professionals and patients, solidifying their market leadership in 2023.

The Retail Pharmacies segment is expected to witness the fastest growth in the BRIC Diabetes Care Devices Market through the forecast period, given greater accessibility, affordability, and patient willingness for easy purchase options. With the growth of retail pharmacy chains and independent pharmacies in urban and rural markets in BRIC countries, diabetes patients have greater access to care devices like blood glucose meters, test strips, insulin pens, and needles. Also, the trend of over-the-counter (OTC) availability of self-monitoring devices and pharmacist-managed diabetes management programs has increased consumer dependence on retail pharmacies. Government efforts in increasing awareness of diabetes and its early detection, as well as increased demand for affordable and easily accessible solutions for diabetes care, are also driving the exponential growth of this segment in the years to come.

By End Use 

The Hospitals segment dominated the BRIC diabetes care devices market with a 41.05% market share in 2023 because of the growing hospitalization rate for diabetes and the rising incidence of diabetes complications that need intensive medical treatment. Hospitals are the main treatment facilities for patients with advanced diabetes, providing sophisticated insulin delivery systems, continuous glucose monitoring (CGM) devices, and emergency treatment for acute complications like diabetic ketoacidosis and hypoglycemia. Also, hospitals are staffed with specialized endocrinology departments offering extensive diabetes management in the form of patient education, monitoring, and individualized treatment plans. Government-sponsored healthcare programs and insurance reimbursement policies for hospitals also reinforce hospital-based diabetes care, hence making hospitals the most favored end-use segment for both diagnosis and long-term control of diabetes among BRIC countries in 2023.

BRIC Diabetes Care Devices Market Regional Insights

Asia Pacific dominated the BRIC diabetes care devices market with a 42.16% market share in 2023 because of the high prevalence of diabetes in the region, rising healthcare spending, and effective government initiatives for diabetes control. China and India, among other countries, have among the highest diabetes rates in the world, with China alone hosting more than 140 million diabetics as of 2023. The increasing knowledge regarding diabetes management, increasing disposable income, and greater access to advanced medical devices have greatly contributed to the uptake of continuous glucose monitors (CGMs) and insulin delivery systems. Furthermore, supportive government initiatives, like China's Volume-Based Procurement (VBP) program, have reduced the costs of critical diabetes care devices. Domestic players are also increasing their footprint, promoting market competition and availability, further solidifying Asia Pacific's dominance in the BRIC Diabetes Care Devices Market.

The Middle East & Africa region is experiencing substantial growth in the BRIC diabetes care devices market with 10.56% CAGR throughout the forecast period, fueled by the growing incidence of diabetes and enhancing healthcare infrastructure. Urbanization, lifestyle changes, and an increase in obesity levels have resulted in a high growth in diabetes cases, especially in the Gulf Cooperation Council (GCC) nations. Regional governments are proactively investing in diabetes education campaigns and national screening programs to encourage early diagnosis and treatment. Moreover, heightened healthcare expenditure, broadening insurance coverage, and collusive collaborations among foreign medical device manufacturers and domestic distributors are enhancing access to sophisticated diabetes care equipment. The increasing focus on digital healthcare and telemedicine technologies in nations such as Saudi Arabia and the UAE is also driving market growth, making the Middle East & Africa a prominent emerging region.

BRIC Diabetes Care Devices Market Key Players

• Medtronic plc (MiniMed 780G Insulin Pump, Guardian Connect CGM System)

• Abbott (FreeStyle Libre CGM System, FreeStyle Optium Neo Blood Glucose Meter)

• F. Hoffmann-La Roche Ltd (Accu-Chek Guide Blood Glucose Meter, Accu-Chek Instant S Blood Glucose Monitoring System)

• Bayer AG (Contour Next Blood Glucose Monitoring System, Breeze 2 Blood Glucose Meter)

• LifeScan, Inc. (OneTouch Verio Flex Blood Glucose Meter, OneTouch Select Plus Simple Glucose Monitor)

• B. Braun SE (Omnican Insulin Pen Needles, Omnican Syringes)

• Dexcom, Inc. (Dexcom G6 CGM System, Dexcom G7 CGM System)

• Insulet Corporation (Omnipod DASH Insulin Management System, Omnipod 5 Automated Insulin Delivery System)

• Ypsomed Holding AG (mylife YpsoPump Insulin Pump, mylife Unio Neva Blood Glucose Monitoring System)

• Sanofi (iBGStar Blood Glucose Monitoring System, AllStar Pro Insulin Pen)

• Novo Nordisk A/S (NovoPen 6 Insulin Pen, NovoFine Plus Needles)

• ARKRAY, Inc. (Glucocard Shine Blood Glucose Meter, Glucocard Expression Blood Glucose Monitoring System)

• Valeritas Holdings, Inc. (V-Go Wearable Insulin Delivery Device, h-Patch Insulin Delivery System)

• Nipro Corporation (TRUEresult Blood Glucose Meter, TRUEbalance Blood Glucose Monitoring System)

• Terumo Corporation (Medisafe With Insulin Pen, FineTouch Insulin Syringes)

• Ascensia Diabetes Care Holdings AG (Contour Plus One Blood Glucose Monitoring System, Contour Next One Glucose Meter)

• AgaMatrix, Inc. (Jazz Wireless 2 Blood Glucose Meter, AgaMatrix WaveSense Blood Glucose Monitoring System)

• Tandem Diabetes Care, Inc. (t: slim X2 Insulin Pump, t: connect Mobile App)

• Senseonics Holdings, Inc. (Eversense XL CGM System, Eversense Bridge CGM System)

• GlySens Incorporated (ICGM Long-term Implantable Continuous Glucose Monitor, Eclipse CGM System)

Suppliers (These suppliers provide essential components, materials, and manufacturing solutions for diabetes care devices, including insulin delivery systems, glucose monitoring devices, and diagnostic equipment.) in the BRIC Diabetes Care Devices Market

• Becton, Dickinson and Company (BD)

• Thermo Fisher Scientific, Inc.

• Siemens Healthineers

• Molex (A Koch Company)

• Freudenberg Medical

• Elkem Silicones

• West Pharmaceutical Services, Inc.

• Jabil Healthcare

• Celanese Corporation

• Phillips-Medisize (A Molex Company)

Recent Development in the BRIC Diabetes Care Devices Market

• August 2024 – Medtronic plc, a global leader in healthcare technology, has received approval from the U.S. Food and Drug Administration (FDA) for its Simplera continuous glucose monitor (CGM). Medtronic's first fully disposable, all-in-one CGM, the device is half the size of Medtronic's prior CGMs. The product has a slim design that simplifies the insertion and wearing process, with no need for overtape.

• August 2024 – Insulet Corporation, the global leader in tubeless insulin pump technology through its Omnipod brand, has received FDA clearance of the Omnipod 5 Automated Insulin Delivery System for the management of type 2 diabetes in people aged 18 years and above in the US. With this achievement, Omnipod 5 is the first and sole FDA-approved Automated Insulin Delivery (AID) system for the management of both type 1 and type 2 diabetes.